Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Advances in Therapy|October 19, 2013
Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studiesRajesh K Rajpal, Raymond Fong, Timothy L Comstock
The American Journal of Managed Care|August 17, 2019
Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and painClifford L Salinger, Bruce I Gaynes, Rajesh K Rajpal
Patient Preference and Adherence|July 17, 2014
Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherenceRajesh K Rajpal, Bryan Ross, Sachin D Rajpal, et al.
Journal of Cataract and Refractive Surgery|December 11, 2012
Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgeryRajesh K Rajpal, Lawrence Roel, Raphaele Siou-Mermet, et al.
Ophthalmology|June 29, 2017
U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive SurgeryPeter S Hersh, R Doyle Stulting, David Muller, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 18, 2011
Intraocular pressure elevations with loteprednol etabonate: a retrospective chart reviewRajesh K Rajpal, Donald Digby, Gerard D'Aversa, et al.
Ophthalmology|May 13, 2017
United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus TreatmentPeter S Hersh, R Doyle Stulting, David Muller, et al.
Cornea|August 2, 2018
Corneal Cross-Linking: Current USA Status: Report From the Cornea SocietyMichael W Belin, Li Lim, Rajesh K Rajpal, et al.
Ophthalmology and Therapy|October 27, 2015
Lasik Xtra® Provides Corneal Stability and Improved OutcomesRajesh K Rajpal, Christine B Wisecarver, Dawn Williams, et al.
American Journal of Ophthalmology|December 15, 2010
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgeryEric D Donnenfeld, Louis D Nichamin, David R Hardten, et al.
Pageof 2